Thoratec takes Q2 loss but expands full-year projection

Despite a jump in device sales, Thoratec's ($THOR) second-quarter profits declined 2.8%, spurred by a 20% increase in operating expenses.

Thoratec's Q2 profits fell to $20.8 million, down from $21.8 million in the same period last year, and the increase in expenses came largely from investments in R&D.

Revenue, however, remains on the up and up, and Thoratec has increased the low end of its annual earnings projection by 4 cents, to $1.24 per share. The company also raised its full-year revenue projection to between $460 million and $470 million, up from the earlier-announced $452 million to $467 million.

Total sales increased by 6.8%, bringing in $118.7 million, and Thoratec's HeartMate line of ventricular pumps brought in $106.2 million on its own, an increase of 9%. The CentriMag blood pump saw its sales increase by 51%, to $8 million, while the company's long-running PVAD line of ventricular support devices declined 50%, to $3.8 million.

The HeartMate II pump, the latest generation in the line, saw its sales rise 13% on the quarter, despite a Class I recall in April. The pump forced Thoratec to issue new implantation instructions for the device after receiving 29 reports about a faulty component that could block blood flow if improperly installed.

In any case, the 6 months ending June 30 were the company's strongest in terms of revenue, CEO Gary Burbach said in a statement, and Thoratec is looking to expand its share in the ventricular assistance device market, plotting pivotal trials for HeartMate III and HeartMate PHP in 2013.

- read Thoratec's release
- get more from The Associated Press

Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.